Sequence Information

    • DRAMP ID

    • DRAMP18084

    • Name

    • Talactoferrin alpha(Lactoferroxin-A)

    • Sequence

    • YLGSGY

    • Description

    • Talactoferrin alfa is a novel immunomodulatory 80 kD protein with demonstrated oral anti-tumor properties. Lactoferrin, a protein found in breast milk is developed by Agennix. It increases body’s immune power and also works as a natural antioxidant, helping to control cell and tissue damage caused by oxidation.

    • Activity

    • Anticancer

    • Target Organism

      • No MICs found on DRAMP database

    • Reference

      • Antimicrobial peptides: therapeutic potential. Expert Opin. Pharmacother. (2006).
      • Oral lactoferrin inhibits growth of established tumours and potentiates conventional chemotherapy. Int. J. Cancer(2004).(PMID: 15221967)
      • Phase I trial of oral talactoferrin alfa in refractory solid tumors.Invest. New Drugs(2006).(PMID: 16193240)

Clinical Information

    • Medical use

    • Combined with chemotherapy in the first-line treatment of advanced non-small cell lung cancer;Topical treatment in diabetic neutropathic ulcers

    • Company

    • Agennix

    • Stage of Development

    • Phase III

    • Comments

    • The trial met its primary end point and the addition of oral talactoferrin to carboplatin/paclitaxel enhanced the patients response to chemotherapy on all tumour-related end points, including response rate, progression-free survival, time to response and duration of response(p = 0.05)

    • Clinical Trials

    • NCT00707304
    • NCT00706862